What is MXCT's market cap?

$135.20M, based on the Nov 5 close of $1.31.

Does MaxCyte pay a dividend?

No regular cash dividend has been paid in the last year.

How much of MXCT is sold short?

1.8M shares, 2.0% of float, as of Oct 15, 2026.

What sector is MXCT in?

Technology, in the R&D — Physical & Biological Sciences industry.

NASDAQ · MXCTTechnologyR&D — Physical & Biological Sciences

MaxCyte, Inc. Common Stock (MXCT)

$1.31−5.76%

Close Nov 5, 2026 · split-adjusted

Nov 5, 2026$1.31▼ 21.56% in range

Nov 5, 2025Low $0.68 · High $1.76Nov 5, 2026

What changed · written from our data

As of Nov 5, 2026

MaxCyte closed at $1.31 on Nov 5, down 5.76%, 25.6% below its 52-week closing high. Volume of 875.0K shares was 0.52× its 20-day average (below normal).

Split-adjusted performance: +26.0% over one month, +50.3% over six months, -18.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $7.27M, down 14.5% from a year earlier, with a net margin of -122.0%.

Short interest was 1.8M shares at the Oct 15 settlement, up 68.1% from the prior report (2.0% of float, 1.1 days to cover).

Market cap$135.2M103.2M shares

Revenue · quarter$7.3M−14.5% YoY

Diluted EPS$-0.08—

P/E · TTM—P/S 4.4×

Net margin-122.0%Gross 77.0%

Dividend yieldNone

52-week range0.68 – 1.76−25.6% from high

Volume875.0K0.52× 20-day avg

Volatility · 60d83.1%Annualised

Short % of float2.0%1.1 days to cover

Net cash$105.7MCash $105.7M

Next earnings—Not scheduled

Split-adjusted performance

1W −24.3%1M +26.0%3M +11.0%6M +50.3%YTD −15.5%1Y −18.6%3Y −55.7%5Y −87.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within R&D — Physical & Biological Sciences

Percentile among 11 companies (100 = best)

6-month momentum70

Revenue growth20

Net margin50

Value (low P/E)—

Size30

Industry medians: 6-month return +48.1%, revenue growth +8.5%, net margin −122.0%, P/E 47.0×.

Short interest

Details →

Shares short1.8M+68.1% vs prior

Days to cover1.1Settled Oct 15

% of float2.0%

Short vol. 10d16.3%of daily volume

Closest peers by size in R&D — Physical & Biological Sciences

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
MXCTMaxCyte	$1.31	−5.76%	+50.3%	−14.5%	−122.0%	—	$135.2M
IBACIB Acquisition	$10.81	−0.46%	−0.2%	—	—	—	$54.1M	Compare
NRCNRC Health	$25.48	−5.87%	+36.0%	+11.0%	12.3%	88.2	$540.7M	Compare
OABIOmniAb	$4.83	−6.76%	+228.6%	+78.3%	−393.9%	—	$704.5M	Compare
ONMDOneMedNet	$4.17	−8.15%	−57.3%	+88.4%	−743.8%	—	$24.3M	Compare
ABSIAbsci	$9.39	−10.40%	+63.3%	−46.4%	−10443.4%	—	$1.61B	Compare
ISPCiSpecimen	$0.8079	−4.16%	−84.7%	−78.7%	−896.9%	—	$2.0M	Compare
BIAFbioAffinity Technologies	$2.60	−11.26%	−91.8%	+19.0%	−222.8%	—	$1.6M	Compare
CRLCharles River Laboratories International	$313.02	−4.07%	+72.3%	−2.7%	−0.1%	—	$15.00B	Compare

News about MaxCyte

All news →

No recent articles focused on MaxCyte. 5 articles mention it in passing.

Quick answers

What does MaxCyte do?: MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development.
What is MXCT's market cap?: $135.20M, based on the Nov 5 close of $1.31.
Does MaxCyte pay a dividend?: No regular cash dividend has been paid in the last year.
How much of MXCT is sold short?: 1.8M shares, 2.0% of float, as of Oct 15, 2026.
What sector is MXCT in?: Technology, in the R&D — Physical & Biological Sciences industry.

About MaxCyte

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

HQ: Rockville, MD91 employeesListed Dec 5, 2019maxcyte.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology